Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

About the PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is the independent resource on PCSK9 science and its translation into critically important new treatments to lower low density lipoprotein cholesterol (LDL-C), which promise to transform the prognosis of millions of patients with hypercholesterolaemia (cholesterol disorders), accelerated atherosclerotic vascular heart disease and a high risk of premature cardiovascular (CV) death and disability.
Aims & ObjectivesMission StatementEditorial BoardPartnership & OutreachForthcoming Meetings

Question of the Month

What’s new on the horizon for lipoprotein(a) therapies?

Prof Henry Ginsberg

Prof Henry Ginsberg (Columbia University, New York, USA) overviews the latest news in novel Lp(a) therapies.
Watch video »

Download Now: New Slide Deck Programme

Previous slide decks focused on landmark studies which used a monoclonal antibody approach to inhibit PCSK9. The next in this series discusses inclisiran, a small interfering RNA therapy, which prevents production of PCSK9 at its primary source in the liver.

Find out more »

News from the Trials

Keep up to date with latest news and analyses from PCSK9 inhibitor trials.

View latest news »

Trial Resources

For expert analysis and insights

View Trials »

View Trial slide decks »

Most viewed

Hot Topics

15th Virtual Closed Scientific Expert Meeting of the Editorial Board
Critical questions in PCSK9 research
Dhruv KaziWhere next for cost-effectiveness analysis of combination LDL lowering therapies?

Dr Dhruv Kazi focuses on future considerations for these analyses.

Watch now

Kiran MusunuruIs a 'once-and-done' approach to LDL lowering feasible?

Prof Kiran Musunuru overviews latest developments with CRISPR base editing of PCSK9.

Watch now

From the Editors

Should ACS patients start a PCSK9 inhibitor in hospital?

Prof Steve Nicholls (Monash University, Australia) puts data from PACMAN-AMI, HUYGENS & GLAGOV in perspective.

Watch video

Watch the video

ACC.22 - PACMAN delivers

Related reports:

HUYGENS

GLAGOV in context

Latest Event

ACC 2022 Scientific sessions 2-4 April

ACC.22 Scientific Sessions
2-4 April, Washington DC

For reportage and expert analysis from:

View all reports »

Meet our Editorial Board

View all our Editorial Board Prof John ChapmanResearch Professor at the University of Pierre and Marie Curie Prof Henry GinsbergDirector, Irving Institute for Clinical and Translational Research Dr Michel FarnierClinician based at Point Medical, Dijon, France Prof Frederick RaalDirector, Carbohydrate & Lipid Metabolism Research Unit Prof Anthony WierzbickiConsultant in Metabolic Medicine/Chemical Pathology